Servier’s $1.5B bet on Edgewise drug fails five months in
7 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
"Servier’s $1.5B bet on Edgewise drug fails five months in" is generating significant coverage in the Business category, with 7 articles from 7 distinct sources tracked by PULSE so far.
Outlets currently covering the story include Fierce Biotech, European Biotechnology Magazine, The Pharma Letter and Muscular Dystrophy Association. PULSE measures a story's velocity from how quickly new articles appear and how many independent newsrooms join the coverage.
This brief was generated by PULSE's extractive engine from coverage metadata only. The latest headlines from every source are listed below; the velocity chart shows how the story is developing in real time.
Generated by PULSE's extractive engine from coverage metadata only — no AI-written claims. Updated 11d ago.
Quick answers
Why is "Servier’s $1.5B bet on Edgewise drug fails five months in" trending?
Because 7 independent news sources published 7 articles about it in a short window — a coverage burst PULSE classifies as a trend.
How does PULSE measure this trend?
PULSE scores velocity from the rate of new articles weighted by source diversity, snapshotted hourly. The full method is public on our methodology page.
Is this trend still active?
The status badge on this page updates hourly: rising, peaking, cooling, or archived once coverage stops for 48 hours.
Coverage (7)
- Servier’s $1.6B muscular dystrophy bet on Edgewise delivers quick-fire pivotal failure Fierce Biotech · 14d ago
- Servier’s $1.55B Edgewise acquisition backfires after Phase 3 setback European Biotechnology Magazine · 14d ago
- Servier’s sevasemten misses muscular dystrophy endpoints The Pharma Letter · 14d ago
- Statement from the Muscular Dystrophy Association on Servier’s Announcement of Topline Results in Becker Muscular Dystrophy Study Muscular Dystrophy Association · 14d ago
- Servier’s $1.55 billion muscular dystrophy drug fails first major test STAT · 14d ago
- Servier Announces Topline Pivotal Results for Sevasemten in Becker Muscular Dystrophy Servier · 14d ago
- Servier’s $1.5B bet on Edgewise drug fails five months in Endpoints News · 14d ago